Biomarin Pharmaceutical Inc. - Registered Shares
BMRN
Market Cap$15.51B
Close$
$102.00
26.1% upsideBiomarin Pharmaceutical - Registered Shares Target Price Details
Target Price by Analysts
26.1% upsideBiomarin Pharmaceutical - Registered Shares Target Price Details$6.11
92.4% downside
Current Fair Value
92.4% downsideOvervalued by 92.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $15.51 Billion |
|---|---|
| Enterprise Value | $15.52 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $0.88 |
| Beta | 0.0 |
| Outstanding Shares | 188,733,789 |
| Avg 30 Day Volume | 1,748,495 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 92.51 |
|---|---|
| PEG | -1.12 |
| Price to Sales | 6.74 |
| Price to Book Ratio | 3.11 |
| Enterprise Value to Revenue | 6.42 |
| Enterprise Value to EBIT | 98.18 |
| Enterprise Value to Net Income | 92 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 0.22 |
Revenue Sources
No data
ESG Score
No data
About Biomarin Pharmaceutical Inc.
CEO: Jean-Jacques Bienaime